Administration and Members

Professor Kevin K . W. Wang, Ph.D.

Title: Director, Center for Neuroproteomics and Biomarkers Research

Executive Director – Center for Neuroproteomics & Biomarker Research

 Associate Professor of Psychiatry and Neuroscience and Physiology

Chief – Translational Medicine

Associate Director, Center for Traumatic Brain Injury Studies

Email: kwang@ufl.edu

Associate Editor, Translational Proteomics (Elsevier)  http://www.journals.elsevier.com/translational-proteomics/

Editorial Board Member,  Journal of Neurotrauma

http://www.liebertpub.com/editorialboard/journal-of-neurotrauma/39/

Council Member,  National Neurotrauma Society  http://www.nationalneurotraumasociety.org/society-information/officers/

Biography:

Dr. Wang obtained his Ph.D. in Pharmaceutical Sciences with Distinction from the University of British Columbia in Vancouver in 1989. He is internationally recognized for his original contributions to the fields of CNS disorders-linked proteolytic enzymes, neuroproteomics and disease biomarker discovery. He joined Parke-Davis Pharmaceutical Research (Ann Arbor, MI) in 1991, and following the company’s merger with Pfizer Inc. (2000), he became Group Leader of CNS Therapeutics/CNS new targets team. He also co-chaired the Far East Scientific Opportunity Team. In 2002, he became Associate Professor of Psychiatry at the University of Florida (Gainesville, FL), Associate Director of the Center for Traumatic Brain Injury Studies and Director of the Center of Neuroproteomics and Biomarkers Research. In 2002, he is a Founder of biotechnology company Banyan Biomarkers Inc. (Alachua, Florida). In 2007, he transitioned to Banyan as full-time Chief Scientific Officer and the Center Director of the Center of Innovative Research. . Dr. Wang has contributed significantly to the discovery, sensitive sandwich ELISA development of two acute TBI protein biomarkers (UCH-L1 and GFAP-BDP) and their diagnostic utility characterization in several animal and human TBI spectrum studies. This TBI biomarker tandem is now in pivotal study for FDA approval as a new first-in-class in vitro diagnostic (IVD) test for mild-moderate TBI (ALERT Trial). In 2011, he rejoined the University of Florida McKnight Brain Institute as Executive Director of the Center of Neuroproteomics and Biomarkers Research /Chief – Translational Research & Associate Professor of Psychiatry and Neuroscience and to rededicate himself to basic and translational research. He is also Chair Professor of the Taipei Medical University.

His research also expanded to proteomic technologies to psychiatric disorders because neuronal injury biomarkers are also highly relevant to psychiatric diseases such as substance abuse and schizophrenia. His laboratory is developing animal model for substance abuse (ecstasy (MDMA), methamphetamine and alcohol abuse, bath salts/designer psychostimulants). In parallel, his group is employing an integrated proteomics-based approach to discover novel biomarkers for these neurological and psychiatric diseases. These technologies include: (1) 2D gel electrophoresis-MALDI-TOF, (2) 2D-LC-MS/MS, (3) CAX-PAGE RPLC-MS/MS, and (4) monoclonal antibody array.

Dr. Wang published more than 200 peer-reviewed papers, reviews and book chapters and co-authored eight US patents. He co-edited four books on proteases, neuroproteomics and biomarkers for CNS disorders. He also serves on five international journal’s Editorial Board. Dr. Wang was Past President  and is current Council member of the National Neurotrauma Society (USA).

His research interests include neuro-proteomics, CNS Injury, neurodegeneration, substance abuse research (methamphetamine, MDMA, nath salts), protein post-translational modification (proteases / protein kinases), biomarkers discovery and assay development, diagnostics, therapeutic development and theranostics.